The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.

NCT04691063 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

486

Enrollment

INDUSTRY

Sponsor class

Conditions

Small-cell Lung Cancer

Interventions

DRUG: SHR-1316; Carboplatin; Etoposide；Radiotherapy
DRUG: Palcebo; Carboplatin; Etoposide；Radiotherapy

Sponsor

Jiangsu HengRui Medicine Co., Ltd.